Navigation Links
TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting
Date:12/7/2009

TAIPEI, Taiwan, Dec. 7 /PRNewswire-Asia/ -- TaiGen Biotechnology Co., Ltd. announced today the presentation of Phase I and preclinical data for TG-0054, the Company's chemokine receptor CXCR4 antagonist and a novel, potent stem cell mobilizer, at the ASH Annual Meeting held in New Orleans, the US, from December 5 to 8, 2009.

The clinical data of Phase 1 study will be presented. In this randomized, double-blind, placebo-controlled, sequential ascending single intravenous dose study, TG-0054 exhibited excellent and favorable safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) profile. A maximally tolerated dose (MTD) was established. Good tolerability was observed. PK parameters showed dose proportionality over the dose range studied. PD results showed potent, dose-dependent mobilization of CD34+ hematopoietic stem cells and CD133+ endothelial progenitor cells into peripheral blood circulation.

The preclinical data will be reported on in vitro assays and in vivo studies in mouse models. TG-0054 demonstrated potent and selective antagonistic activities against CXCR4 in vitro. Significant mobilization of CD34+ hematopoietic stem cells and CD133+ endothelial progenitor cells was observed when TG-0054 was used alone or combined with G-CSF in preclinical models.

The preclinical and Phase I results support further clinical investigation. The Phase 2 study entitled "A Phase II, Randomized, Open-Label, Multi-Center Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 in Patients with Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease" will begin to enroll patients in December, 2009.

    ASH 2009 Meeting Presentation:

    Clinical
    Oral presentation: TG-0054, a Novel and Potent Stem Cell Mobilizer,
                       Displays Excellent PK/PD and Safety Profile in Phase 1
                       Trial
    Tuesday, Decem
'/>"/>
SOURCE TaiGen Biotechnology Co., Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
2. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
3. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
4. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
5. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
6. Genetic Engineering & Biotechnology News Reports on the Growing Role of Ion-Channel Studies in Global Biotech R&D
7. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
8. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
9. Dr. Ari Kiev to be Featured Speaker at Biotechnology Conference Wall Street Unplugged: The Trout Group Investor Seminar in New York July 30
10. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
11. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , September 17, 2014 ... Market by Component (Sensor, Battery, Memory Device, Display, & ... Fitness & Wellness), and by Geography - Global Forecast ... medical electronics market is expected to reach $56.50 Billion ... 2014 to 2020. Browse 235 market data ...
(Date:9/17/2014)... WOONSOCKET, R.I. , Sept. 17, 2014 ... provides insights regarding patients taking Sovaldi® (sofosbuvir), a new ... The data shows that over the last several months ... and actual downward trend in Sovaldi utilization. This suggests ... number of new therapeutic regimens of similar efficacy and ...
(Date:9/17/2014)...  The law firm McElroy, Deutsch, Mulvaney & ... serve as host for "Show Me the Money: ... Healthcare Reform," a one-day conference scheduled for October ... compliance and enforcement in a marketplace re-shaped by ... -  http://photos.prnewswire.com/prnh/20140916/146606 Logo -  http://photos.prnewswire.com/prnh/20140916/146607 ...
Breaking Medicine Technology:Medical Electronics Market Worth $56.50 Billion by 2020 2Medical Electronics Market Worth $56.50 Billion by 2020 3Medical Electronics Market Worth $56.50 Billion by 2020 4CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 2CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 3CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 4Three Leading Healthcare Organizations Sponsor Conference to Examine Opportunities and Risks of Healthcare Reform for Providers 2
... July 20 BIO Ventures for Global Health (BVGH) announced ... a new San Francisco headquarters office. The expansion provides BVGH the ... communities on both coasts. , , ... very excited about our expansion and new location in the Bay area, one ...
... Pathologists Outlines Recommendations at Food and Drug Administration Meeting , ... WASHINGTON , ... tests in diagnosing and treating disease, representatives of the College of ... Administration (FDA) urging increased oversight of laboratory developed tests (LDTs) and ...
Cached Medicine Technology:BIO Ventures for Global Health Opens San Francisco Office; Hires New Senior Staff 2BIO Ventures for Global Health Opens San Francisco Office; Hires New Senior Staff 3CAP Leaders Stress Need for Oversight of Direct-to-Consumer and Laboratory Developed Tests 2CAP Leaders Stress Need for Oversight of Direct-to-Consumer and Laboratory Developed Tests 3CAP Leaders Stress Need for Oversight of Direct-to-Consumer and Laboratory Developed Tests 4
(Date:9/17/2014)... for the very healthy. Astronauts are selected for ... psychological standards to prepare them for any unknown ... average people can now fly for enjoyment. The ... about what medical conditions or diseases should be ... most medical conditions have never been studied for ...
(Date:9/17/2014)... research study was announced today that will analyze ... long-term wellness and contribute to healthy aging. ... and funded through a $10 million unrestricted gift ... WELL aims to identify lifestyle and environmental factors ... wellness as they age. WELL will be designed, ...
(Date:9/17/2014)... September 17, 2014 People who struggle to ... head to http://www.perwickstrom.com and get the answer by ... to point out, is that a business plan and a ... work together, commented Per Wickstrom. “The way I view it ... a business strategy which is part two.” , According ...
(Date:9/17/2014)... (HealthDay News) -- Social networking sites can help people ... people who are obese, sites like Twitter and Facebook ... from doctors as well as peers, researchers found. ... is that it offers the potential to be much ... compared to traditional approaches," the study,s lead author, Dr. ...
(Date:9/17/2014)... manipulation these sound like the ideas of ... are components of an exciting new approach to ... models of metastatic prostate cancer, scientists at Virginia ... Molecular Medicine and Johns Hopkins Medical Institutions have ... that could revolutionize doctors, ability to see tumors ...
Breaking Medicine News(10 mins):Health News:Space: The final frontier… open to the public 2Health News:First-ever research study examines impacts of diet and lifestyle on healthy aging 2Health News:Per Wickstrom’s Latest Blog Explores the Difference Between a Business Plan and a Business Strategy 2Health News:Social Networking Sites Can Help Obese Lose Weight: Study 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3
... Nursing Facility,Funding Cut, COLUMBUS, Ohio, June 18 ... American Health Care Association (AHCA) today,praised Ohio Congressman ... the growing bipartisan effort in Congress to prevent,the ... to,seniors, Medicare Part A nursing home funding - ...
... June 18 /PRNewswire/ - Media representatives are invited,to a ... and Arnold Schwarzenegger, the California Governor, in light of ... at the BIO 2008 International Convention in San Diego., ... Minister of Health ...
... don,t take meds regularly, study says , , WEDNESDAY, June 18 ... times more likely to die if they fail to take ... , The study also found that these people -- who ... every 10 occasions over a three-month period -- had an ...
... of patients with inflammatory bowel disease (IBD) who undergo ... lower volumes of IBD patients, according to a new ... in Milwaukee. ,The study also found a ... undergo surgery for Crohn,s Disease, a form of IBD, ...
... guidelines to ensure quality ... pace with growth in new subspecialty field, ... training standards for the emerging interventional,cardiology subspecialty field ... and Interventions (SCAI) announced today the,creation of The ...
... to the growing number of,Staph and MRSA cases ... Solutions to offer advanced antimicrobial solutions for,sports facilities ... antimicrobial program designed to protect the,facilities and equipment ... includes the treatment of lockers, uniforms, weight rooms, ...
Cached Medicine News:Health News:Boehner Thanked for Opposing Funding Cut to Medicare Beneficiaries 2Health News:Failure to Take Seizure Drugs Boosts Death Risk 2Health News:Choice of hospital impacts outcomes for inflammatory bowel disease surgery 2Health News:SCAI Creates New Council for Rising Interest in Interventional Therapies for Structural Heart Disease 2Health News:SCAI Creates New Council for Rising Interest in Interventional Therapies for Structural Heart Disease 3Health News:Pioneering Solutions To Fight Staph, MRSA Infections in Sports Facilities and Synthetic Turf Fields 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: